|
Medical network - on March 14, the pharmaceutical industry has nearly 20000 registration certificate, annual product registration fee includes the new registration and continue to register products such as new cost hundreds of millions of yuan, about 10% of industry profits.
On March 5th, the prime minister at the 12th National People's Congress the fifth meeting of the government work report points out: "the expansion of small micro enterprises enjoy preferential income tax has halved the scope of the upper limit of the taxable income amount by 300000 yuan to 500000 yuan; research and development of small and mid-sized enterprise claim additional deduction expenses increased from 50% to 50%, one thousand ways to make structural tax cuts and effect to further revealed." At the same time, "to reduce the corporate tax 350 billion yuan, enterprises throughout the year is about 200 billion yuan, be sure to let the market main body feeling."
Tax problems have always been including pharmaceutical industry and other manufacturing watches. The National People's Congress, the people big pharmacy chain co., LTD., chairman of Xie Zilong in an interview with reporters, points out that the real economy because the cost is higher, such as tax and profit margin is very low, lead to a lot of people are not willing to do the real economy, the or affect the potential risk of economic sustainable development.
To this end, a number of deputies to the national CPPCC and multiple industries association several related Suggestions are put forward. As the representative of the National People's Congress, shandong xinhua medical instrument co., LTD., chairman of Zhao Yixin in relevant symposium pointed to the reporter, "the two meetings" at the present stage enterprise VAT rate is high, enterprise management burden is heavy, suggest to establish a rational standard of the charges, reduce the corporate tax rate, support the development of in vitro diagnostic industry.
Big drug firms charge pressure
Our country enterprise's tax burden for many years has been the hot topic in society. At the end of last year, cao has detonated opinion "ran" topic.
In August of 2015, China international capital corporation, issued the cut taxes should not miss the steady growth and restructuring, research reports, data disclosure of macro tax burden in China reached 37% in 2015. This value is lower than the developed countries, however, the level of 42.8%.
"Medical machinery industry, for example, the industry profit margins are relatively high, value-added tax, the real economy at the same time operating burden is heavy, industry raw material costs, product prices are lower, loan financing difficulties, enterprises encountered new difficulties, combined with the market expectations of tax cuts and the global impact, these changes reduce the industry enterprise competitiveness, some companies hard to survive." Zhao Yixin told reporters.
Due to the pharmaceutical industry tax is heavier, in recent years a large number of drug companies choose to set up companies in Tibet, because Tibet is tax depressions. Camp at the same time, the pharmaceutical industry has been calling for lower taxes and fees, to change, after two votes, such as policy, drug firms feel more direct fiscal pressures.
Released by the China federation of logistics and purchasing logistics industry situation analysis report pointed out that the logistics enterprises generally reflect the "change" camp after the tax burden, such as in kyushu tong pharmaceutical group five logistics enterprises, after the "battalion to add" tax rate rose by 72.74%.
Additional as we have learned, at present there are nearly 20000 registration certificate, the pharmaceutical industry product registration fee includes the new annual registration and perpetuation of registered products such as new cost hundreds of millions of yuan, accounting for about 10% of the profits. In vitro diagnostic industry, for example. In vitro diagnostic product varieties and more varieties of a single sales volume small, the enterprise generally has hundreds of registration certificate of the product in the production; Medical institutions inspection cost down at the same time, drive the enterprise growth in the market.
To this, the China association for medical devices industry advice: "the national development and reform commission, the state food and drug supervision and management of administration and other relevant departments according to the project fee problem research, formulate reasonable charging standards."
And the China association for pharmaceutical biotechnology relevant personage also pointed out that due to the pharmaceutical industry once every 5 years to GMP transformation, production workshop air conditioning equipment should be updated, when calculating the property tax requirements will be included in the tax base. "This for pharmaceutical biotechnology company, a lot of pressure to pay taxes every year."
In view of the change of national policy has had a huge impact on the development of industry, China pharmaceutical biotechnology association recommends that relevant departments should strengthen the legislation after evaluation, solve the problem of good regulation effect, to the detriment of the industrial development laws and regulations shall be revised in time.
"Suggested changes to the regulations on the management of blood products, plasma and let go of components in allocating, plasma resources concentrated to large-scale enterprises; promote timely assessment about the flow of vaccine and its impact on industries of the New Deal, suggest collectivize management, integrated operation group company belongs to the production of the enterprise as a temporary library, each other between the warehouse storage and transportation to each other, in order to ensure the entire conform to the requirements of the cold chain transportation, improve the efficiency of distribution and response time." Chinese medicine biotechnology association said.
The personage inside course of study points out that our country enterprise systems and mechanisms through the years of accumulation of taxes and fees burden heavier problem has not been at ease, all kinds of high transaction cost especially institutional transaction cost problems still outstanding.
In fact, the management of macroeconomic policies and measures in project funding directly controversial, widely criticized for a long time.
"The hand of the government departments at all levels in our country still has a lot of policy project funding, with various kinds of methods of examination and approval red tape, project name, taken by supply and demand between long channel into the real economy." The industry insiders said.
To this, the China association for medical devices industry is recommended, the fiscal and taxation authorities to reduce the VAT tax burden, reduce the burden of enterprise management, make medical instrument industry can get healthy development.
Pharmaceutical research and development enterprise "pain points"
Public information, the lack of pharmaceutical r&d tax preferential policies, the state r&d claim additional deduction of incentives, but there are challenges in the concrete practice, makes a lot of major research and development type drug firms is less than half of the r&d can enjoy preferential, for a lot of financial system is not sound a greater role in small and medium-sized enterprises.
Reporters learned that the personage inside the industry, at present the industry to technology transfer tax preferential policy is yet to be clear. According to the regulation, biological medicine technology transfer of new varieties of more than RMB 5 million yuan not levy, but there is no clear what is "biological medicine varieties.
Put forward by the prime minister's government work report claim additional deduction small and mid-sized enterprise research and development expenses increased from 50% to 50%, one thousand ways to make structural tax cuts and effect further, for research and development type drug firms will no doubt have experience.
National development put forward many requirements for drug firms, such as the consistency evaluation of chemical medicine TCM injections effectiveness evaluation again, and so on. Drug firms in conducting the research and development project, should pay attention to research and development program and tax filing work, to enjoy the of the preferential policies granted by the state to the claim additional deduction r&d cost, reduce the enterprise income tax.
, medical association recommends that, on expanding our scope of r&d expenses deducted pre-tax basis to pharmaceutical companies outside of the cost of new drug clinical applied category, encourage technology transfer; In addition to cancel the "research and development expenses, other related fees shall not exceed the total claim additional deduction can be 10% of the total development costs", further burden for the enterprise.
Claim additional deduction claim additional deduction "policy while on the one hand, to expand the scope, reduce the corporate tax burden, but on the other hand, enterprises entrust overseas institutions or individuals to the costs of r&d activity claim additional deduction shall not, for drug firms, is not conducive to foreign advanced technology introduction and digestion and absorption." Relevant personage says medical association.
At the same time, in view of the problems existing in the medical industry, the relevant personage also points out that should play a role of the national industrial policies to guide, national industrial policy consideration shall be given to the pharmaceutical industry the whole industry chain, guide enterprises to carry out original research. To encourage research and development of new technology at the same time, indicate the way should be in time for the transformation and industrialization.
In fact, in the face of rising cost of enterprise production and management problems, reduce business operating costs and speed the theme of the macroeconomic policy shift period. In the past two years, the state council on tax cuts JiangFei cost reduction initiatives such as deployment for many times, at the local level cost reduction plan is dense, enterprise tax burden relief, all kinds of transaction costs, especially institutional significantly lower transaction cost, cost reduction action positive policy effects are obtained. |
